2 drugs on their way to phase three trials. Simple process, with protection of intellectual capital.
Will target $11bn p.a. US pain relief market
Very experienced board (Resmed) and lots of cash following underwritten rights issue.
Unfairly punished following rights issue at 80cents.
This one will hopefully allow me to retire.
Add to My Watchlist
What is My Watchlist?